评价药源性心脏毒性生物标志物的研究进展  

Research progress in evaluating biomarkers of pharmacogenic cardiotoxicity

作　　者：程昱 李美凤 李艳芬[1,2] 舒文沁 文湄伊[1] CHENG Yu;LI Meifeng;LI Yanfen;SHU Wenqin;WEN Meiyi(Graduate School,Tianjin University of Traditional Chinese Medicine,Tianjin 300000,China;Department of Clinical Pharmacy,the Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine,Tianjin 300000,China)

机构地区：[1]天津中医药大学研究生院,天津300000 [2]天津中医药大学第二附属医院临床药理科,天津300000

出　　处：《广州医药》2025年第1期48-55,共8页Guangzhou Medical Journal

基　　金：天津市教委科研计划项目(2021KJ168);天津市卫生健康委员会中医中西医结合课题(2023073)。

摘　　要：药源性心脏毒性是临床常见的药物不良反应,是药物研发和临床治疗需面临的严峻考验。对药源性心脏毒性的评价是目前研究的重点,基于其机制复杂多样、临床表现不一、影响因素多,早期评价具有困难。生物标志物是评价心脏毒性的重要指标之一,文章总结了目前已经报道的多种心脏毒性标志物及其潜在的生物标志物,希望能从中找到特异性强、敏感性高的标志物,以贡献于药物心脏安全性评价工作。As a common clinical adverse reaction,pharmacogenic cardiotoxicity is a severe challenge for drug development and clinical treatment.The evaluation of pharmacogenic cardiotoxicity is the focus of current research,and early evaluation is difficult with its complex and diverse mechanisms,varying clinical manifestations,and numerous influencing factors.Biomarker is an important index to evaluate cardiotoxicity.This article summarizes a variety of cardiotoxicity biomarkers and other potential biomarkers that have been reported so far,hoping to find biomarkers with strong specificity and high sensitivity,so as to contribute to the evaluation on cardiac safety of drugs.

关 键 词：药源性 心脏毒性 生物标志物 

分 类 号：R73[医药卫生—肿瘤]